Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clinton F Stewart

Showing results (181-190 of 220) with videos related to

Pageof 22
Sort By:
Neuro-Oncology|April 11, 2023
Genetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumorsAustin L Brown, Pagna Sok, Kimberly P Raghubar, et al.
Neuro-Oncology|February 11, 2004
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposiumRamsis K Benjamin, Fred H Hochberg, Elizabeth Fox, et al.
JAMA Oncology|November 20, 2015
Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood OsteosarcomaMichelle N Edelmann, Vinay M Daryani, Michael W Bishop, et al.
Journal of Neuro-Oncology|November 30, 2005
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology groupMurali M Chintagumpala, Henry S Friedman, Clinton F Stewart, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|May 2, 2015
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium studyLindsey M Hoffman, Maryam Fouladi, James Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumorsWayne L Furman, Fariba Navid, Najat C Daw, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 20, 2015
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumorsMark W Kieran, Susan Chi, Stewart Goldman, et al.
Journal of Neuro-Oncology|April 11, 2015
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)Mariko DeWire, Maryam Fouladi, David C Turner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine gliomaAlberto Broniscer, Justin N Baker, Michael Tagen, et al.
Molecular Cancer Research : MCR|June 21, 2007
Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculaturePaxton V Dickson, John B Hamner, Christian J Streck, et al.
Pageof 22

Showing results (181-190 of 220) with videos related to

Sort By:
Pageof 22
Neuro-Oncology|April 11, 2023
Genetic susceptibility to cognitive decline following craniospinal irradiation for pediatric central nervous system tumorsAustin L Brown, Pagna Sok, Kimberly P Raghubar, et al.
Neuro-Oncology|February 11, 2004
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposiumRamsis K Benjamin, Fred H Hochberg, Elizabeth Fox, et al.
JAMA Oncology|November 20, 2015
Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood OsteosarcomaMichelle N Edelmann, Vinay M Daryani, Michael W Bishop, et al.
Journal of Neuro-Oncology|November 30, 2005
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology groupMurali M Chintagumpala, Henry S Friedman, Clinton F Stewart, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|May 2, 2015
Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium studyLindsey M Hoffman, Maryam Fouladi, James Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumorsWayne L Furman, Fariba Navid, Najat C Daw, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 20, 2015
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumorsMark W Kieran, Susan Chi, Stewart Goldman, et al.
Journal of Neuro-Oncology|April 11, 2015
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)Mariko DeWire, Maryam Fouladi, David C Turner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine gliomaAlberto Broniscer, Justin N Baker, Michael Tagen, et al.
Molecular Cancer Research : MCR|June 21, 2007
Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculaturePaxton V Dickson, John B Hamner, Christian J Streck, et al.
Pageof 22